Predicting MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma by whole-tumour texture analysis combined with clinical and conventional contrast-enhanced computed tomography features

Lei Miao ¹, Tian Qiu ², Yan Li ²

⁰Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Translational Lung Cancer Research +

|

July 8, 2024

View abstract on PubMed

Summary

Predicting MET exon 14 skipping mutations in pulmonary sarcomatoid carcinoma (PSC) is crucial for targeted therapy. Whole-tumour texture analysis combined with CT features offers a noninvasive method to identify these mutations in PSC patients.

Area Of Science

Oncology
Radiology
Genetics

Background

Pulmonary sarcomatoid carcinoma (PSC) is a rare, aggressive non-small cell lung cancer (NSCLC).
MET exon 14 skipping mutations are actionable targets in NSCLC.
Accurate prediction of these mutations is vital for guiding treatment decisions.

Purpose Of The Study

To develop and validate a noninvasive method for predicting MET exon 14 skipping mutations in PSC.
To evaluate the efficacy of whole-tumour texture analysis combined with clinical and conventional CT features.

Main Methods

Retrospective analysis of 56 PSC patients with pathology-confirmed diagnosis.
Whole-tumour texture analysis and conventional contrast-enhanced CT (CECT) feature extraction.
Next-generation sequencing (NGS) for MET exon 14 skipping mutation detection.
Multivariate logistic regression for predictive model development.

Main Results

MET exon 14 skipping mutation detected in 17.9% of PSC patients.
Mutations associated with smaller tumour dimensions, lower T stages, and specific enhancement patterns.
Combined texture and conventional CT model achieved the highest AUC (0.89) for prediction.

Conclusions

Whole-tumour texture analysis integrated with clinical and CECT features shows promise as a noninvasive tool.
This approach can aid in predicting MET exon 14 skipping mutation status in PSC.
Facilitates personalized treatment strategies for PSC patients.

Keywords:

MET exon 14 skipping (METex14 skipping) Pulmonary sarcomatoid carcinoma (PSC) computed tomography (CT) texture analysis